Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Payables (2016 - 2025)

Regenxbio (RGNX) has 12 years of Payables data on record, last reported at $21.4 million in Q4 2025.

  • For Q4 2025, Payables fell 6.32% year-over-year to $21.4 million; the TTM value through Dec 2025 reached $21.4 million, down 6.32%, while the annual FY2025 figure was $21.4 million, 6.32% down from the prior year.
  • Payables reached $21.4 million in Q4 2025 per RGNX's latest filing, down from $22.3 million in the prior quarter.
  • Across five years, Payables topped out at $31.4 million in Q1 2024 and bottomed at $9.4 million in Q2 2021.
  • Average Payables over 5 years is $20.0 million, with a median of $21.5 million recorded in 2025.
  • Peak YoY movement for Payables: surged 138.98% in 2022, then plummeted 39.27% in 2025.
  • A 5-year view of Payables shows it stood at $11.4 million in 2021, then skyrocketed by 138.98% to $27.2 million in 2022, then fell by 16.27% to $22.8 million in 2023, then rose by 0.05% to $22.8 million in 2024, then decreased by 6.32% to $21.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $21.4 million in Q4 2025, $22.3 million in Q3 2025, and $21.7 million in Q2 2025.